CDER Says Keeping Avastin Breast Cancer Claim Would Undermine Accelerated Approval Process
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Center for Drug Evaluation and Research intends to argue at a June hearing that the accelerated approval system will operate as a lower standard if bevacizumab's breast cancer indication is maintained while Genentech conducts another confirmatory trial.
You may also be interested in...
Cancer Approval Standards, FDA Reputation At Stake With Avastin Hearing, NEJM Authors Say
In separate perspective pieces in the New England Journal of Medicine, Boston academics criticize the 2008 approval of bevacizumab's breast cancer claim based on progression-free survival and warn the agency's credibility will be undermined if the claim is not withdrawn.
Cancer Approval Standards, FDA Reputation At Stake With Avastin Hearing, NEJM Authors Say
In separate perspective pieces in the New England Journal of Medicine, Boston academics criticize the 2008 approval of bevacizumab's breast cancer claim based on progression-free survival and warn the agency's credibility will be undermined if the claim is not withdrawn.
Genentech Banking On Biomarker Data To Save Avastin In Breast Cancer
Genentech is counting on biomarker data gathered across the Avastin development program – in addition to a new assay developed by parent company Roche – to help it retain the VEGF inhibitor’s accelerated approval in metastatic breast cancer.